Home  /  Resource Library  /  Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Treatment with single-agent ibrutinib can increase susceptibility to PCP in chronic lymphocytic leukemia patients. Key components of PCP diagnosis are increased clinical suspicion and adequate sampling with diagnostic bronchoscopy.